Revelation Biosciences Inc (REVB)

Jun 13, 2026

Revelation Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView

Jun 13, 2026

Jun 12, 2026

REVB SEC FilingsRevelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 12, 2026

Jun 08, 2026

REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; No Revenue ReportedEPS Revision Trend - newsline.com

Jun 08, 2026

Jun 07, 2026

REVB Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageCFO Commentary Report - newsline.com

Jun 07, 2026

Jun 04, 2026

Revelation Biosciences forms advisory board for AKI trial - Investing.com

Jun 04, 2026

Jun 03, 2026

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Newark Advocate

Jun 03, 2026

Jun 02, 2026

Revelation Biosciences expands AKI advisory board - Investing.com UK

Jun 02, 2026

Jun 01, 2026

Revel Releases Updated Corporate Presentation and Posts It to Website - TradingView

Jun 01, 2026

Jun 01, 2026

Revelation Biosciences (NASDAQ: REVB) furnishes new corporate presentation - Stock Titan

Jun 01, 2026

Jun 01, 2026

Revelation Biosciences expands AKI advisory board By Investing.com - Investing.com South Africa

Jun 01, 2026

Jun 01, 2026

Revelation Biosciences Expands Acute Kidney Injury Advisory Board - Rutland Herald

Jun 01, 2026

May 29, 2026

REVB Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue StageSubscription Growth Report - newsline.com

May 29, 2026

May 29, 2026

Revelation Biosciences (REVB) Shows Minimal Movement as Shares Trade Near Key SupportTime Weighted Price - newsline.com

May 29, 2026

May 28, 2026

REVB Q1 2026 Earnings: Significant EPS Miss as Cash Burn Continues Without RevenueReturn On Assets - thelegaladvocate.com

May 28, 2026

May 27, 2026

Revelation Biosciences (REVB) Inches Higher, Holding Above Key Support at $1.02Bear Pennant - The Legal Advocate

May 27, 2026

May 27, 2026

REVB Q1 2026 Earnings: Significant EPS Miss Amid Early-Stage DevelopmentEarnings Revision Downgrade - The Legal Advocate

May 27, 2026

May 27, 2026

REVB Q1 2026 Earnings: Staggering EPS Miss Highlights Ongoing Clinical Development CostsBook Value Growth - The Legal Advocate

May 27, 2026

May 26, 2026

Revelation Biosciences Inc. (REVB) Edges Lower, Maintains Support Near $1.01Exhaustion Gap - The Legal Advocate

May 26, 2026

May 26, 2026

REVB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesEarnings Outlook Update - newsline.com

May 26, 2026

May 25, 2026

Revelation Biosciences (REVB) Faces Slight Decline as Key Support Levels Are TestedWave Extension - The Legal Advocate

May 25, 2026

May 23, 2026

Revelation Biosciences Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue StageStock Analysis Community - Newser

May 23, 2026

May 22, 2026

Revelation Biosciences Inc. (REVB) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentEarnings Yield Spread - Newser

May 22, 2026

May 22, 2026

Revelation Biosciences (REVB) Consolidates Near Key Support at $1.03Institutional Grade Picks - Newser

May 22, 2026

May 22, 2026

REVB Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Awaits Clinical MilestonesEPS Surprise History - The Legal Advocate

May 22, 2026

May 20, 2026

Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet - Bez Kabli

May 20, 2026

May 18, 2026

Revelation Biosciences (REVB) Stock Forum and Discussion - Moomoo

May 18, 2026

May 18, 2026

Revelation Biosciences (REVB) Climbs +4.51% — Resistance at $1.07 in Focus 2026-05-18Community Risk Signals - Newser

May 18, 2026

May 15, 2026

Revelation Biosciences, Inc.Common Stock (NQ: REVB - The Chronicle-Journal

May 15, 2026

May 15, 2026

Armistice Capital reports 323,241 REVB shares (REVB) — 7.80% stake disclosed - Stock Titan

May 15, 2026

May 14, 2026

Revelation Biosciences announces pricing of $4M public offering - MSN

May 14, 2026

May 13, 2026

TradingKey - TradingKey

May 13, 2026

May 12, 2026

REVB Stock Price, Quote & Chart | REVELATION BIOSCIENCES INC (NASDAQ:REVB) - ChartMill

May 12, 2026

May 11, 2026

Revelation Biosciences (NASDAQ: REVB) seeks wide reverse split authority in 2026 proxy - Stock Titan

May 11, 2026

May 11, 2026

Revelation Biosciences releases proxy materials with CEO update - Investing.com

May 11, 2026

May 11, 2026

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders - The Joplin Globe

May 11, 2026

May 11, 2026

How one 300-patient trial could unlock a new acute kidney injury treatment - Stock Titan

May 11, 2026

May 08, 2026

The edge Revelation Biosciences (REVB) has in a competitive landscape (Risk Aversion) 2026-05-08Verified Stock Signals - Newser

May 08, 2026

May 07, 2026

EX-99.1 - SEC.gov

May 07, 2026

May 07, 2026

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 - Times Argus

May 07, 2026

May 07, 2026

Q1 2026 results for Revelation Biosciences (NASDAQ: REVB) detailed - Stock Titan

May 07, 2026

May 07, 2026

FDA agrees to single Gemini study for acute kidney injury - Stock Titan

May 07, 2026

May 07, 2026

BRIEF-Revelation Biosciences Inc Q1 EPS USD -2.71 - TradingView

May 07, 2026

May 07, 2026

Revelation Biosciences (REVB) Q1 loss widens as cash runway and going concern risks emerge - Stock Titan

May 07, 2026

May 07, 2026

Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 07, 2026